Madrigal Pharmaceuticals Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals or view top-rated stocks.

6 analysts have issued twelve-month target prices for Madrigal Pharmaceuticals' shares. Their MDGL stock forecasts range from $111.00 to $220.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $167.43 in the next year. This suggests a possible upside of 133.1% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Madrigal Pharmaceuticals' stock was trading at $84.74 on January 1st, 2022. Since then, MDGL shares have decreased by 15.2% and is now trading at $71.83.
View the best growth stocks for 2022 here.

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($3.36) earnings per share for the quarter, beating analysts' consensus estimates of ($3.75) by $0.39. During the same period in the prior year, the business earned ($3.32) EPS.
View Madrigal Pharmaceuticals' earnings history.

Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of MDGL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.11%), BlackRock Inc. (5.59%), Wellington Management Group LLP (5.27%), Deep Track Capital LP (4.60%), State Street Corp (4.48%) and Federated Hermes Inc. (2.00%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals.

MDGL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Goldman Sachs Group Inc., Citigroup Inc., Parkman Healthcare Partners LLC, Group One Trading L.P., Northern Trust Corp, Metropolitan Life Insurance Co NY, and Royal Bank of Canada. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last two years include Bay City Capital Llc, and Fred B Craves.
View insider buying and selling activity for Madrigal Pharmaceuticals or view top insider-selling stocks.

MDGL stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Deep Track Capital LP, State Street Corp, Vanguard Group Inc., Jane Street Group LLC, SG Americas Securities LLC, Dimensional Fund Advisors LP, and Campbell & CO Investment Adviser LLC.
View insider buying and selling activity for Madrigal Pharmaceuticals or or view top insider-buying stocks.

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDGL stock can currently be purchased for approximately $71.83.

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $1.23 billion. The biopharmaceutical company earns $-241.85 million in net income (profit) each year or ($14.650010) on an earnings per share basis.

Madrigal Pharmaceuticals employs 71 workers across the globe.

Madrigal Pharmaceuticals was founded in 2011.

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at [email protected], or via fax at 781-274-8228.